BrainChild Bio, a spinout from Seattle Children’s Hospital, has raised $116 million in Series A financing to develop CAR-T cell therapies for rare, deadly childhood brain cancers.
What sets it apart is where the cells go. Instead of infusing engineered immune cells into the bloodstream, BrainChild uses locoregional delivery — administering CAR-T cells directly into the brain. That leverages the blood-brain barrier to keep the cells localized, potentially reducing dangerous body-wide side effects like cytokine release syndrome.
The pipeline
The lead program, BCB-276, is in Phase 2 for diffuse intrinsic pontine glioma (DIPG) — a brainstem tumor that strikes roughly 300 U.S. children a year and is almost uniformly fatal. It targets the B7-H3 protein and, notably, needs no chemotherapy conditioning, allowing repeat dosing (primary completion expected 2028). A second program, BCB-214, is in preclinical development for glioblastoma and could enter human trials next year.
Why it matters
CAR-T has transformed blood cancers but struggled against solid and brain tumors. “The prejudice is that the brain would be intolerant to having cells directly administered,” said founder Michael Jensen — a assumption BrainChild is built to challenge. Investors include Seattle Children’s and the Washington Research Foundation’s venture arm. For families facing diagnoses like DIPG, where options are few, even early progress carries outsized weight — though these therapies are still in trials.